In the March issue of MedNous, Dr Paula Salmikangas and Dr Björn Carlsson address the challenges related to the development of novel gene therapies.

Gene therapy products now have the potential to cure severe conditions such as cancer and fundamentally alter the trajectory of many other severely disabling diseases by engineering the correct functionality of cells or genes.

In the article, Paula and Björn share their insights on the selection of viral vectors and the pros and cons related to the different types of vectors. When developing gene therapies, one major hurdle is the lack of in vivo models to generate safety data. Paula and Björn also explore the decisions that needs to be considered when moving a potential gene therapy from the pre-clinical phase to first in human studies. The article also covers the clinical evidence generation and what impact the usually small patient populations have on the safety data.

Download

The Authors

Dr Paula Salmikangas

Advisory Board Director

Read more

Dr Björn Carlsson

Principal Consultant / Advisory Board Member

Read more

 

Stay up to date

Contact us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World